457 related articles for article (PubMed ID: 29183235)
1. Pneumococcal conjugate vaccine use for the prevention of pneumococcal disease in adults <50 years of age.
Isturiz RE; Hall-Murray C; McLaughlin JM; Snow V; Schmoele-Thoma B; Webber C; Thompson A; Scott DA
Expert Rev Vaccines; 2018 Jan; 17(1):45-55. PubMed ID: 29183235
[TBL] [Abstract][Full Text] [Related]
2. 13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.
Plosker GL
Drugs; 2015 Sep; 75(13):1535-46. PubMed ID: 26242768
[TBL] [Abstract][Full Text] [Related]
3. Pneumococcal conjugate vaccine use in adults - Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia.
Sings HL
Vaccine; 2017 Sep; 35(40):5406-5417. PubMed ID: 28602602
[TBL] [Abstract][Full Text] [Related]
4. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
Webber C; Patton M; Patterson S; Schmoele-Thoma B; Huijts SM; Bonten MJ;
Vaccine; 2017 Mar; 35(9):1266-1272. PubMed ID: 28173960
[TBL] [Abstract][Full Text] [Related]
5. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).
LeBlanc JJ; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang ALS; Gillis HD; Martin I; Demczuk W; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy AE; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
Vaccine; 2019 Aug; 37(36):5466-5473. PubMed ID: 31345638
[TBL] [Abstract][Full Text] [Related]
6. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.
Suaya JA; Jiang Q; Scott DA; Gruber WC; Webber C; Schmoele-Thoma B; Hall-Murray CK; Jodar L; Isturiz RE
Vaccine; 2018 Mar; 36(11):1477-1483. PubMed ID: 29429807
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
[TBL] [Abstract][Full Text] [Related]
8. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
[TBL] [Abstract][Full Text] [Related]
9. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.
Sherwin RL; Gray S; Alexander R; McGovern PC; Graepel J; Pride MW; Purdy J; Paradiso P; File TM
J Infect Dis; 2013 Dec; 208(11):1813-20. PubMed ID: 24092845
[TBL] [Abstract][Full Text] [Related]
10. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly.
Huijts SM; van Werkhoven CH; Bolkenbaas M; Grobbee DE; Bonten MJM
Vaccine; 2017 Aug; 35(34):4444-4449. PubMed ID: 28410813
[TBL] [Abstract][Full Text] [Related]
11. The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?
van Werkhoven CH; Bonten MJ
Future Microbiol; 2015; 10(9):1405-13. PubMed ID: 26347153
[TBL] [Abstract][Full Text] [Related]
12. Herd effects of child vaccination with pneumococcal conjugate vaccine against pneumococcal non-invasive community-acquired pneumonia: What is the evidence?
van Werkhoven CH
Hum Vaccin Immunother; 2017 May; 13(5):1177-1181. PubMed ID: 27937061
[TBL] [Abstract][Full Text] [Related]
13. Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.
Link-Gelles R; Taylor T; Moore MR;
Vaccine; 2013 May; 31(22):2572-7. PubMed ID: 23583813
[TBL] [Abstract][Full Text] [Related]
14. Vaccine strategies for prevention of community-acquired pneumonia in Canada: Who would benefit most from pneumococcal immunization?
Kaplan A; Arsenault P; Aw B; Brown V; Fox G; Grossman R; Jadavji T; Laferrière C; Levitz S; Loeb M; McIvor A; Mody CH; Poulin Y; Shapiro M; Tessier D; Théorêt F; Weiss K; Yaremko J; Zhanel G
Can Fam Physician; 2019 Sep; 65(9):625-633. PubMed ID: 31515311
[TBL] [Abstract][Full Text] [Related]
15. Pneumococcal conjugate vaccine use in adults.
Isturiz RE; Schmoele-Thoma B; Scott DA; Jodar L; Webber C; Sings HL; Paradiso P
Expert Rev Vaccines; 2016; 15(3):279-93. PubMed ID: 26651847
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial.
Solanki BB; Juergens C; Chopada MB; Supe P; Sundaraiyer V; Le Dren-Narayanin N; Cutler MW; Gruber WC; Scott DA; Schmoele-Thoma B
Hum Vaccin Immunother; 2017 Sep; 13(9):2065-2071. PubMed ID: 28881165
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
[TBL] [Abstract][Full Text] [Related]
18. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Gruber WC; Grobbee DE; Bonten MJM; Jodar L
Vaccine; 2019 Jul; 37(30):4147-4154. PubMed ID: 31155413
[TBL] [Abstract][Full Text] [Related]
19. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
20. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]